KCT0005368尚未招募未知
Efficacy and safety of Hominis placenta pharmacopuncture on mild cognitive impairment: Randomized, Double blind, Placebo-controlled, Multi-center Trial
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional Study
入排标准
- 年龄范围
- 50(Year) 至 80(Year)（—）
- 性别
- All
入选标准
- •1) Male or female adult aged 50 to 80.
- •2) A person diagnosed with mild neurocognitive impairment based on DSM-5.
- •3) A person who can undergo neuropsychological tests and complete questionnaires.
- •4) A person who agrees to participate in the trial after receiving explanations regarding the purpose and procedures involved in the clinical trial and has signed the informed consent form by oneself or one’s legal representative.
- •5) A person with a score of 0.5 on the CDR.
排除标准
- •1) A person with a cranial lesion or brain injury that can cause cognitive decline.
- •2) A person with a history of cerebral hemorrhage or cerebral infarction.
- •3) A person with brain diseases such as Parkinson’s disease, epilepsy, and brain cancer.
- •4) A person with a present illness or past history of a major psychiatric disorder such as schizophrenia, delusional disorder, depressive disorder, bipolar disorder, or alcohol or substance abuse disorder as diagnosed using DSM-5.
- •5) A person who has participated in other clinical trials within the last one month.
- •6) A person who had acupuncture treatment for cognitive impairment within the last four weeks.
- •7) A person who is currently taking medication related to dementia (If the person is diagnosed with MCI and is taking dementia-related drugs, he/she may participate in the clinical trial after the wash-out period of 15 days).
- •8) A person with a severely destabilizing general medical condition (a doctor in charge will judge the enrollment based on the results of laboratory tests, vital signs, etc.).
- •9) A person with a clinically serious liver disease or with serum aspartate transaminase and alanine transaminase levels exceeding twice the upper limit of reference value.
- •10) A person with chronic renal failure or with serum blood urea nitrogen and creatinine levels exceeding 1.5 times the upper limit of reference value.
- •11) Pregnant woman, lactating woman, or woman of childbearing potential who do not use appropriate methods of contraception.
- •12) A person who researchers judge to be inappropriate for participation in this clinical trial.
- •13) A person who is hypersensitive to H. placenta and other drugs.
- •14) A person with moderate complications other than those involving the heart, liver, and kidney.
- •15) A person with psychogenic diseases.
研究者
相似试验
招募中
2 期
Safety and efficacy of exosome Injection in perianal fistulaIRCT20211212053361N1Tehran University of Medical Sciences15
尚未招募
Unknown
Effectiveness of placenta mesenchymal stem cell-derived exosomes on embryo implantation rate in women with recurrent implantation failureRecurrent Implantation Failure.Complication associated with artificial fertilization, unspecifiedN98.9IRCT20130812014333N223Kermanshah University of Medical Sciences15
招募中
1 期
human placenta in the treatment of skin wrinklesskin wrinkles.Other specified disorders of the skin and subcutaneous tissueL98.8IRCT20210612051545N3Tehran University of Medical Sciences20
尚未招募
不适用
Is there any benefit of using a topical gel prepared from human body to improve wound healing after laser gum lightening procedure?CTRI/2022/07/043850Dr Shubhankar Mehrotra
已完成
不适用
Hominis Placenta Pharmacopuncture for treating insomnia disorderKCT0005127Pusan National University Korean Medicine Hospital51